Arkolith/Insider Trading/TNGX/Form 4

Crystal Adam

President, R&DTango Therapeutics, Inc. (TNGX) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$226K
Net Open-Market Flow
-$226K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2026Sell(S)201$12.90$3K187K
Feb 3, 2026Sell(S)18K$12.26$224K187K
Feb 2, 2026Grant(A)47K—$0206K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 2, 2026Grant(A)285K—$0285K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-038052) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML